The Efficacies of The New Paclitaxel-Eluting CoroflexTM Please Stent in Percutaneous Coronary Intervention

Exclusion Criteria

• •1. The patient has a known hypersensitivity or contraindication to any of the following medications:
• •* Heparin
• •* Aspirin
• •* Both Clopidogrel and Ticlopidine
• •* Paclitaxel
• •* Stainless steel
• •* Contrast media(\*) (\*)Patients with documented sensitivity to contrast media which can be effectively pre-medicated with steroids and diphenhydramine \[e.g. rash\] may be enrolled. Those with true anaphylaxis to prior contrast media, however, should not be enrolled.
• •2. Systemic (intravenous) Paclitaxel use within 12 months.
• •3. Female of childbearing potential, unless a recent pregnancy test is negative, who possibly plan to become pregnant any time after enrollment into this study.
• •4. History of bleeding diathesis or known coagulopathy (including heparin- induced thrombocytopenia), or will refuse blood transfusions.
• •5. Gastrointestinal or genitourinary bleeding within the prior 3 months, or major surgery within 2 months.
• •6. An elective surgical procedure is planned that would necessitate interruption of thienopyridines during the first 6 months post enrollment.
• •7. Non-cardiac co-morbid conditions are present with life expectancy \<1 year or that may result in protocol non-compliance (per site investigator's medical judgment).
• •8. Patients who are actively participating in another drug or device investigational study, which have not completed the primary endpoint follow-up period.
• •9. Patients with LVEF\<25% or those with cardiogenic shock
• •10. Patients with acute ST elevation myocardial infarction who requires primary PCI
• •11. Patients with acute ST elevation myocardial infarction within 48hrs
• •12. Creatinine level ≥ 3.0mg/dL or dependence on dialysis.
• •1. Patients with significant left main stem stenosis which requires revascularization therapy
• •2. Patients who's target lesion has in-stent restenosis at the stented segment of drug-eluting stents or bare metal stents
• •3. Target lesions with bifurcating disease which require side branch stenting